
VIVINEX IMPRESS™
BE IMPRESSED
Set a new benchmark for visual outcomes achieved by your monofocal patients
HOYA
SURGICAL OPTICS

Vivinex Impress™ enhances the intermediate vision of monofocal patients

Vivinex Impress™ IOL

RANGE OF VISION NEAR INTERMEDIATE FAR

Standard monofocal aspheric IOL

Vivinex Impress™ provides greater than 1 line of binocular visual acuity improvement at 66 cm

Interim results of a running multicentre study[1]

Binocular Defocus



Vivinex Impress™ provides the same best-corrected mean distance acuity as a standard monofoal aspheric IOL[1]

Vivinex Impress™ improves intermediate visual acuity at 66 cm (-1.5 D defocus) by more than 1 line[1]

Vivinex Impress™ improves intermediate vision and provides consistant refractive predictability

Monocular distance-corrected visual acuity at 1 month[1]



- No difference in best-corrected mean distance visual acuity at 4 m between Vivinex Impress™ and a standard monofocal aspheric IOL[1]
- Approximately 1 line improvement in distance-corrected visual acuity at 66 cm in the Vivinex Impress™ group[1]

Absolute value deviation from target postop spherical equivalent at 1 month[1]



- Refractive predictability was excellent in both Vivinex Impress™ and the standard monofocal aspheric groups[1]
  - within 0.25 D of target: 60 % vs 55 %
  - within 0.50 D of target: 87 % vs 77 %
  - within 0.75 D of target: 100 % vs 91 %

So how does Vivinex Impress™ work?

Topographic representation of the Vivinex Impress™ anterior surface illustrates power variations

Representation of Vivinex Impress™ side view

Representation of light refracted by the Vivinex Impress™ optic to create an extended range of focus



This image is for illustrative purposes only and is not an exact representation of the product.

The central optical element creates variations in power that provide an extended range of focus and improved intermediate vision. Vivinex Impress™ looks the same as a standard monofocal IOL.[2]

Benefits of the Vivinex™ platform

Glistening-free Glistening-free hydrophobic acrylic IOL material[3,4]

Improved Image Quality Incorporates the Vivinex™ proprietary aspheric optic design which partially compensates for corneal spherical aberration and is more tolerant to sources of coma than standard aspheric designs[5]

Reduction of PCO Active oxygen processing treatment, a smooth surface and square optic edge to reduce PCO[3,6,7,8,9,10,11,12]

Smooth IOL unfolding and capsular bag stability Textured rough haptic surface designed to reduce potential for adhesion to the optic surface during delivery, and provides better grip inside the capsular bag



Delivered in the preloaded multiSert™ injector

Push and screw modes and the ability to control insertion depth
Vivinex™ multiSert™ is a 4-in-1 delivery system that allows you to achieve outstanding delivery consistency with your choice of injection and insertion style[13]





Delivery into capsular bag
insert shield:
Default position

Delivery through incision wound tunnel
insert shield:
Advanced position

Preloaded injectors are:

Easier to prepare, increasing safety by:[14,15,16,17,18,19]
- Reducing risk of contamination and infection
- Reducing risk of IOL damage

More efficient in the OR:[16,18]
- Minimising time spent preparing the IOL delivery system
- Creating fewer instruments to reprocess

More predictable:[18]
- Increasing predictability and consistency of IOL delivery

Specifications

	Vivinex Impress™
Model name	XY1-EM
Optic design	Biconvex with square, thin and textured optic edge Anterior: Aspheric design
Optic & haptic materials	Hydrophobic acrylic Vivinex™ with UV- and blue light filter
Haptic design	Textured-rough haptic surface
Diameter (optic/OAL)	6.00 mm / 13.00 mm
IOL Power (Spherical equivalent)	+6.00 D to +30.00 D in increments of 0.50 D
Nominal A-constant*	118.8
Injector	**multiSert™** preloaded
Front injector tip outer diameter	1.70 mm
Recommended incision size	2.20 mm



> Please refer to the datasheet for full specifications.

*The A-constant is presented as a starting point for the lens power calculation.
When calculating the exact lens power, it is recommended that calculations be performed individually, based on the equipment used and operating surgeon's own experience.

Delivered by the **multiSert™** preloaded injector



CE 0123 2023-08-15_HSOE_XY1-EM_BR_EN

References: 1. HOYA data on file. CTM-23-P0105, HOYA Medical Singapore, Pte. Ltd, 2023 **2.** HOYA data on file RnD-20-367, HOYA Medical Singapore, Pte. Ltd, 2023 **3.** Tandogan, T. et al. (2021): In-vitro glistening formation in six different foldable hydrophobic intraocular lenses. In BMC Ophthalmol 21, 126. **4.** Auffarth et al. (2023) Randomized multicenter trial to assess posterior capsule opacification and glistenings in two hydrophobic acrylic intraocular lenses. Sci Rep 13, 2822. **5.** Pérez-Merino, P.; Marcos, S. (2018): Effect of intraocular lens decentration on image quality tested in a custom model eye. In: Journal of cataract and refractive surgery 44 (7), p. 889–896. **6.** Leydolt, C. et al. (2020): Posterior capsule opacification with two hydrophobic acrylic intraocular lenses: 3-year results of a randomized trial. In: American journal of ophthalmology 217 (9), p. 224-231. **7.** Giacinto, C. et al. (2019): Surface properties of commercially available hydrophobic acrylic intraocular lenses: Comparative study. In: Journal of cataract and refractive surgery 45 (9), p. 1330–1334. **8.** Werner, L. et al. (2019): Evaluation of clarity characteristics in a new hydrophobic acrylic IOL in comparison to commercially available IOLs. In: Journal of cataract and refractive surgery 45 (10), p. 1490–1497. **9.** Matsushima, H. et al. (2006): Active oxygen processing for acrylic intraocular lenses to prevent posterior capsule opacification. In: Journal of cataract and refractive surgery 32 (6), p. 1035–1040. **10.** Farukhi, A. et al. (2015): Evaluation of uveal and capsule biocompatibility of a single-piece hydrophobic acrylic intraocular lens with ultraviolet-ozone treatment on the posterior surface. In: Journal of cataract and refractive surgery 41 (5), p. 1081–1087. **11.** Eldred, J. et al. (2019): An In Vitro Human Lens Capsular Bag Model Adopting a Graded Culture Regime to Assess Putative Impact of IOLs on PCO Formation. In: Investigative ophthalmology & visual science 60 (1), p. 113–122. **12.** Nanavaty, M. et al. (2019): Edge profile of commercially available square-edged intraocular lenses: Part 2. In: Journal of cataract and refractive surgery 45 (6), p. 847–853. **13.** HOYA data on file. DoF-SERT-102-MULT-03052018, HOYA Medical Singapore Pte. Ltd, 2018 **14.** Galor, A. er al. (2013). Management strategies to reduce risk of postoperative infections. In Current ophthalmology reports, 1(4), 10.1007/s40135-013-0021-5. **15.** Bodnar, Z. et al. (2012). Toxic anterior segment syndrome: Update on the most common causes. In: Journal of cataract and refractive surgery, 38(11), 1902–1910. **16.** Jones, J. et al. (2016). The impact of a preloaded intraocular lens delivery system on operating room efficiency in routine cataract surgery. In: Clinical ophthalmology (Auckland, N.Z.), 10, 1123–1129. **17.** Park, C. et al. (2018). Toxic anterior segment syndrome-an updated review. In: BMC ophthalmology, 18(1), 276. **18.** Chung, B. et al. (2018). Preloaded and non-preloaded intraocular lens delivery system and characteristics: human and porcine eyes trial. In: International journal of ophthalmology, 11(1), 6–11. **19.** Schmidbauer, J. et al. Rates and causes of intraoperative removal of foldable and rigid intraocular lenses: clinicopathological analysis of 100 cases. In: Journal of cataract and refractive surgery, 28(7), 1223–1228.

HOYA Medical Singapore Pte. Ltd. | 455A Jalan Ahmad Ibrahim | Singapore 639939.
HOYA Surgical Optics GmbH | De-Saint-Exupery-Str. 10 | 60549 Frankfurt am Main | Germany | Hotline DE: Tel. +49 (0)800 664 2 664 | Fax +49 (0)800 774 2 774 **hoyasurgicaloptics.com**